Table 1.
Characteristics of the COVID-19 population.
| Overall 1532 |
Age groups N (%) | ||||
|---|---|---|---|---|---|
| 0–39 years 319 (20.8) |
40–59 years 553 (36.1) |
60–79 years 514 (33.6) |
≥ 80 years 146 (9.5) |
||
| Sex N (%) | |||||
| Male | 926 (60.4) | 189 (59.2) | 335 (60.6) | 338 (65.8) | 64 (43.8) |
| Female | 606 (39.6) | 130 (40.8) | 218 (39.4) | 176 (34.2) | 82 (56.2) |
| Mean age ± SD | 55 (± 19) | 27 (± 9) | 51 (± 5) | 68 (± 6) | 85 (± 4) |
| Prevalence of drug use (%) | 74.54 | 49.53 | 69.98 | 89.49 | 93.84 |
| Median number of prescriptions (IQR) | 16 (5–42) | 3 (1–6) | 9 (3–20) | 28 (13–54) | 51 (29–71) |
| Polypharmacy group, N (%) | |||||
| 0 drugs | 387 (25.5) | 161 (50.5) | 163 (29.5) | 54 (10.5) | 9 (6.2) |
| No polypharmacy (1–4 drugs) | 600 (39.2) | 145 (45.5) | 264 (47.7) | 168 (32.7) | 23 (15.8) |
| Polypharmacy (5–9 drugs) | 351 (22.9) | 13 (4.1) | 101 (18.3) | 179 (34.8) | 58 (39.7) |
| Excessive polypharmacy (≥ 10 drugs) | 194 (12.7) | – | 25 (4.5) | 113 (22.0) | 56 (38.4) |